As one of nine pharmaceutical companies worldwide, AstraZeneca is in the crucial test phase for a corona vaccine.
But the study has to be suspended.
AstraZeneca
is considered to be a great hope in the development of a
corona vaccine
.
But now the British-Swedish pharmaceutical company has
to stop the clinical test phase
.
Here you will find the basic facts about the coronavirus * and the corona news from Germany.
We also offer you the current number of cases in Germany on a map.
Update from September 10, 2020, 2:05 p.m.:
Research into a
vaccine
is considered one of the key factors to combat the
Sars-Cov-2 coronavirus
.
But now there was a major setback.
The British-Swedish pharmaceutical company
AstraZeneca
had to interrupt the third and therefore last phase of the clinical studies because
health problems occurred
in a
test person
.
Corona vaccine: study stopped - subject probably has "syndrome to be taken very seriously"
The group has so far remained covered with regard to the exact disease.
According to information from the
"New York Times"
(we reported, see first report), however, it is said to be
transverse myelitis
, an inflammation of the spinal cord.
In many cases this would recede completely, but "this is a syndrome to be taken very seriously", as the head of the Infectious Disease Department at Regensburg University Clinic, Professor
Bernd Salzberger
, told the "Bild" newspaper (article behind the payment barrier).
A time delay is now inevitable.
Dr.
Rolf Hömke
, research
sprecer of
the Association of Research-
Based
Pharmaceutical Companies, told the newspaper that the study "could be continued after a few days or weeks".
The spokesman for Health Minister
Jens Spahn
said that it was "the scientific standard" for a study to be stopped because of health problems of a participant.
Coronavirus: vaccine test stopped - test subject probably got sick with a rare disease
Our initial report from September 9, 2020:
Munich - All over the world people long for a
vaccine
to be able to fight the corona pandemic * effectively.
A company is well advanced in developing a serum.
The British-Swedish pharmaceutical company
AstraZeneca
is one of nine companies worldwide in the third and final phase of clinical studies and is considered a great hope.
Tests with tens of thousands of participants were running.
Corona vaccine: AstraZeneca has to interrupt the test phase
But in the race to get a vaccine * approved,
AstraZeneca has
now suffered a major setback.
The clinical was stopped for the time being
because one of the subjects had health problems
.
This is a routine measure "that must be carried out whenever a potentially inexplicable disease occurs in one of the studies," said a company spokesman.
He went on to say that the process had been voluntarily interrupted "in order to allow the safety data to be checked by an independent committee." It was necessary to clarify whether the health problems of the study participant were due to side effects of the active ingredient AZD1222.
Tests for corona vaccine interrupted: patient is said to have rare neurological disease
AstraZeneca
did not provide any information
about the disease or where the patient is
.
But there are conjectures and rumors.
The
New York Times claims
to have learned from an informed person that the patient is said to have transverse myelitis.
This is a rare neurological disorder caused by inflammation of the central nervous system caused by viruses.
Breaking News: A major coronavirus vaccine trial was halted because of a serious adverse reaction in a participant, the pharmaceutical company AstraZeneca said.
https://t.co/PC4EYqPr1c
- The New York Times (@nytimes) September 8, 2020
The
active ingredient AZD1222 manufactured
by
AstraZeneca
is based on the weakened version of a cold virus from chimpanzees and is supposed to get the immune system going so that it can fight Sars-CoV-2 * in the event of infection.
(mt / dpa) * Merkur.de is part of the nationwide Ippen digital editorial network.
List of rubric lists: © Ted S. Warren / dpa